



University of Southern Denmark

Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers A Randomized Placebo-Controlled Trial

Perri, Giorgia; Hill, Tom R.; Mathers, John C.; Walsh, Jennifer S.; Gossiel, Fatma; Winther, Kristian; Frölich, Jacob; Folkestad, Lars; Cold, Søren; Eastell, Richard

Published in:

Journal of Bone and Mineral Research

DOI:

10.1002/jbmr.4703

Publication date:

2022

Document version:

Final published version

Document license:

CC BY

Citation for published version (APA):

Perri, G., Hill, T. R., Mathers, J. C., Walsh, J. S., Gossiel, F., Winther, K., Frölich, J., Folkestad, L., Cold, S., & Eastell, R. (2022). Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled Trial. *Journal of Bone and Mineral Research*, 37(11), 2165-2173. <https://doi.org/10.1002/jbmr.4703>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.

Unless otherwise specified it has been shared according to the terms for self-archiving.

If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Thank you to our 2018-2022 JBMR Associate and Deputy Editors



more than 3,500 paper
recommendations!

Journal of Bone and Mineral Research
JBMR

Lorenz Hofbauer
Fernando Rivadeneira
Jen Westendorf
Bjorn Busse
Laura Calvi
Thomas Carpenter
Emma Duncan
X. Edward Guo
Karl Jepsen
Benjamin Leder
Christa Maes
Allison Pettit
Elizabeth Samelson
Ann Schwartz
Natalie Sims
Chan Soo Shin
Marjolein van der Meulen
Tuan Nguyen
Deborah Veis
Kate Ward



Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled Trial

Giorgia Perri,¹ Tom R Hill,¹ John C Mathers,¹ Jennifer S Walsh,² Fatma Gossiel,² Kristian Winther,^{3,4,5} Jacob Frölich,³ Lars Folkestad,^{3,6} Søren Cold,⁷ and Richard Eastell²

¹Human Nutrition Research Centre, Centre for Healthier Lives, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

²Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK

³Department of Endocrinology, Odense University Hospital, Odense, Denmark

⁴Centre for Diabetes, Academic Specialist Centre, Stockholm, Sweden

⁵Department of Molecular Medicine and Surgery, Karolinska Institute, Solna, Sweden

⁶Department of Clinical Research, University of Southern Denmark, Odense, Denmark

⁷Department of Oncology, Odense University Hospital, Odense, Denmark

ABSTRACT

Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long-term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N-terminal propeptide (PINP), collagen type I cross-linked C-telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60–74 years) were randomized to receive placebo-yeast versus 100, 200, or 300 µg selenium as selenium-enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose-response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 µg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 µg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 µg/L for 100, 200, and 300 µg supplemental selenium/d, respectively ($p < 0.001$)). There was no change in plasma selenium concentration in the placebo-treated group. There was no significant effect of selenium supplementation on OC (6 months $p = 0.37$; 5 years $p = 0.63$), PINP (6 months $p = 0.37$; 5 years $p = 0.79$), CTX (6 months $p = 0.91$; 5 years $p = 0.58$) or BALP (6 months $p = 0.17$; 5 years $p = 0.53$). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health. © 2022 The Authors. *Journal of Bone and Mineral Research* published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

KEY WORDS: BIOCHEMICAL MARKERS OF BONE TURNOVER; GENERAL POPULATION STUDIES; NUTRITION

Introduction

Globally, 0.5 to 1 billion individuals are selenium deficient with blood concentrations below 70 µg/L. Inadequate selenium status in humans impairs the expression of the consortium

of selenoproteins that are the biologically active selenium-containing molecules.⁽¹⁾ Selenium intakes vary greatly⁽¹⁾; residents of Europe, New Zealand, central Africa, and some parts of China have insufficient selenium intake due to low soil selenium. Among Europeans, selenium intakes declined⁽²⁾ from

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Received in original form May 3, 2022; revised form September 1, 2022; accepted September 5, 2022.

Address correspondence to: Giorgia Perri, PhD Student, Human Nutrition Research Centre, Centre for Healthier Lives, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.

E-mail: g.perri1@newcastle.ac.uk

Additional Supporting Information may be found in the online version of this article.

Journal of Bone and Mineral Research, Vol. 37, No. 11, November 2022, pp 2165–2173.

DOI: 10.1002/jbmr.4703

© 2022 The Authors. *Journal of Bone and Mineral Research* published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

60–63 µg/d to 29–39 µg/d from 1970 to 2000.^(2,3) In Denmark, selenium intake fell from 51 to 42 µg/d during 1990–95,⁽⁴⁾ and plasma selenium concentration dropped from 42 to 37 µg/L between 1995–2000 and 2002.^(5,6) However, among older adults, aged 65 to 75 years, intakes increased from the study period by approximately 25 µg/d between 1995–2001 and 2011–2013.⁽⁷⁾

In humans, selenium deficiency is associated with muscle fatigue, pain, weakness, and increased serum concentration of creatine kinase.^(8,9) Compared with selenium-supplemented mice, selenium-deficient mice had higher concentrations of inflammatory markers and bone resorption markers with poorer bone microarchitecture.⁽¹⁰⁾ Similarly, abnormal skeletal growth and poor bone health was observed in selenium-deficient rats,^(11–13) whereas selenium supplementation improved bone microarchitecture.⁽¹⁴⁾

When incorporated into selenoproteins, selenium is important for musculoskeletal function. Most selenoproteins are involved in redox reactions, reducing concentrations of reactive oxygen species (ROS), such as hydrogen peroxide.^(15,16) Multiple studies have shown an inverse relationship between selenium status and inflammatory molecules, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α).⁽¹⁷⁾ Both ROS and pro-inflammatory molecules (e.g. IL-6, TNF-α) can initiate bone resorption.^(18,19) Because selenoproteins are expressed within osteoblasts and osteoclasts,⁽²⁰⁾ the bone formation and resorption cells, respectively, they may regulate bone resorption by moderating oxidative stress through ROS reduction.^(14,21,22) Higher ROS concentrations increase bone loss through the RANK pathway.⁽²³⁾ Participants with lower selenium status have higher concentrations of IL-6^(17,24) and supplementation with 200 µg selenium daily for 12 weeks reduced IL-6 concentration.⁽²⁵⁾ Concentrations of IL-6 are higher in osteoporotic individuals.^(23,26,27) In addition, higher selenium concentrations are associated with higher bone mineral density (BMD) and lower bone turnover markers (BTM).⁽²⁸⁾ NHANES data suggested that higher selenium status (mean 131.1 µg/L) in US individuals, especially postmenopausal women, was positively associated with femur BMD.⁽²⁹⁾ Consequently, improving selenium status could be an effective and inexpensive approach to reducing the age-related decline in bone health. A recent randomized controlled trial (RCT) in 120 postmenopausal women showed that supplementation with sodium selenite for 6 months did not affect bone turnover or BMD.⁽³⁰⁾ Our study aims to extend the findings from this investigation by Walsh and colleagues⁽³⁰⁾ by using both men and women, a larger sample size, and a longer study duration.

This study tested the hypothesis that long-term supplementation with selenium improves bone health in older adults. We investigated the long-term effects of selenium supplementation on biomarkers of bone turnover through secondary analysis of data from a 5-year trial of adults in Denmark who were randomized to supplements providing 100, 200, or 300 µg selenium/d or to a placebo.

Subjects and Methods

PRECISE study

Data was obtained from the Danish Prevention of Cancer by Intervention with Selenium (PRECISE): A Pilot Study. The study began in 1998 and ended in 2004 and was organized by the Selenium Centre, Odense University Hospital, Denmark. It aimed to assess the viability for a full randomized controlled trial and hypothesized that selenium supplementation would reduce cancer risk in healthy adults. The trial was registered ([ClinicalTrials.gov](#)

gov ID: NCT01819649) and other outcomes from the study have been published.^(31,32) The regional Data Protection Agency and Scientific Ethical Committees of Vejle and Funen counties approved the study (Journal Number 19980186). The present study is a secondary analysis to determine the effect of selenium supplementation on biomarkers of bone turnover.

Participants

Using a random sample from the Danish Civil Registration, invitation letters were sent to 2897 men and women aged 60 to 74 years from the County of Funen between November 1998 and June 1999. Of these, 630 accepted the invitation and were screened for inclusion (Supplemental Table S1). A nonfasted blood sample was collected from those meeting the inclusion criteria, and placebo yeast tablets were provided during a 4-week run-in phase to determine compliance. At the second visit, participant satisfaction and adherence (>80% of tablets taken using tablet counts⁽³¹⁾) were assessed. After this, 491 participants met the inclusion and adherence criteria for continuation. All participants provided written informed consent.

Randomization

The eligible 491 participants were enrolled in a randomized, double-blinded, non-stratified, single-center, parallel clinical trial with four experimental arms distributed as 1:1:1:1 placebo (yeast tablet; $n = 126$), 100 µg selenium/d ($n = 124$), 200 µg selenium/d ($n = 122$), or 300 µg selenium/d ($n = 119$). There were 482 participants with BTM measurements. One participant was removed (see Statistical Analyses below); therefore, participants with BTMs at baseline were $n = 124, 122, 118,$ and 117 for placebo, 100, 200, and 300 µg selenium/d, respectively (Fig. 1), giving a total of 481 participants. The study used computer-generated, blocked, and non-stratified randomization conducted by the Division of Epidemiology and Biostatistics, Arizona Cancer Centre, University of Arizona. Couples living at the same address were provided with the same intervention supplementation dose for practical reasons, i.e. to prevent mixing of selenium doses. The responsibility of distributing the tablets was placed with pharmacists at Odense University Hospital. Participants, research staff, and investigators were blinded to supplementation doses.⁽³¹⁾

Intervention

The selenium was provided as selenium-enriched yeast (in tablet form) in 100, 200, and 300 µg doses. These doses were suggested to be safe, as the tolerable upper intake level for adversity, set by the Institute of Medicine, is 400 µg/d.⁽³³⁾ The SelenoPrecise tablets (prepared by Pharma Nord ApS, Vejle, Denmark) contained 54% to 60% of total selenium as selenomethionine (SeMet) with unknown seleno compounds providing the remainder.⁽³⁴⁾ The placebo was identical to the supplementation tablets and consisted of inactive, spray-dried baker's yeast (250 µg yeast placebo, 80 µg cellulose, 65 µg dicalcium phosphate, and ≤5 µg of inactive ingredients). Smell and taste were matched by coating all tablets in titanium oxide, and tablets were packaged as 28-tablet blister packs.

Participant characteristics were determined at baseline. Further evaluations were performed at 6, 12, 18, 24, 36, and 60 months, which included assessment of medical status, tablet count, records of side effects, and the provision of new tablets, as previously described.⁽³¹⁾




Fig. 1. Number of participants with bone turnover marker data at each stage of the study and dropout reasons.

Biochemical analyses

Nonfasting blood samples were collected at baseline, 6 months, and 5 years. Plasma was prepared and stored at -80°C .

Plasma selenium

Total selenium in plasma ($\mu\text{g/L}$) was measured at baseline, 6 months, and 5 years by LGC Limited using inductively coupled plasma mass spectrometry with external calibration (described in Cold and colleagues⁽³¹⁾). The selenium concentration for the certified reference standard BCR-637 was 78.3 (SD 2.7) $\mu\text{g/L}$ (16 independent replicates), indicating good accuracy of the method. High-selenium concentrations had an intra-assay coefficient of variation (CV) of 0.5%, whereas low-selenium concentrations had an intra-assay CV of 3%. The interassay CV was 3.4%.

Bone turnover markers

The rationale for choice of the selected BTMs is described in Supplemental Table S2.⁽³⁵⁾ PINP and CTX were selected because they are the two reference markers recommended by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry for inclusion of all studies using bone turnover markers.⁽³⁶⁾ Additionally, they have been associated with selenium and selenoprotein P in the OPUS study,⁽²⁸⁾ where OC was more closely associated with selenoprotein P than PINP.⁽²⁸⁾ Studies suggest BALP can help identify changes in bone mineralization such as osteomalacia and Paget's disease.⁽³⁷⁾

The BTMs were analyzed in 2017, with study recruitment from 1998–1999 until 2004. Thus, the oldest study samples were 19 years old, and the most recent ones were 13 years old. Studies have suggested that BTMs are stable when stored at -80°C for longer periods of time.^(38,39) Serum was analyzed from the baseline, 6-month, and 5-year time points for N-MID osteocalcin (OC, measuring the large 1–43 N-mid and the intact OC), procollagen type I N-terminal propeptide (PINP, measuring the trimer only), collagen type I cross-linked C-telopeptide (CTX), and bone alkaline phosphatase (BALP) at the Bone Biochemistry Laboratory, Department of Oncology and Metabolism, University of Sheffield (England). OC, PINP, CTX, and BALP were measured using the IDS-iSYS automated immunoassays (Immunodiagnostic Systems, Boldon, UK). The interassay CVs were 5.0%, 7.2%, 6.5%, and 3.5% for OC, PINP, CTX, and BALP, respectively.

Covariates

Data on covariates were collected during visits with trained research nurses. Body mass index (BMI) was calculated as kg weight/m^2 height (continuous). Participants were classified into education status using surveys based on time spent in education after public school (0 = no, 1 = 1–3 years, 2 = 3–4 years, 3 = above 4 years). Living status was determined as living alone (0 = no, 1 = yes). Smoking status was determined at baseline (0 = never, 1 = previous, 2 = current). Alcohol intake was reported as standard drinks per week (continuous). Medication usage (thyroid,

antiresorptives, glucocorticoids [GC], hormone replacement therapy [HRT]) was classified as a binary variable depending on the medication (0 = no, 1 = yes), with thyroid medication having three categories (0 = none, 1 = levothyroxine, 2 = antithyroid drugs). Supplementation usage (calcium, vitamin D, multivitamins) was classified as a binary variable (0 = no, 1 = yes).

Statistical analyses

Data were analyzed using the IBM (Armonk, NY, USA) statistical software package version 24.0 (SPSS). A p value < 0.05 was considered statistically significant. To determine the normality of the variables, quantile–quantile (QQ) plots were used. Log 10 transformation was applied to all BTM measurements to normalize the data. Participant baseline characteristics are presented according to the supplementation dose. Differences in characteristics across supplementation doses were assessed using chi-square test (categorical) or Kruskal–Wallis (ordered and non-normally distributed). Data were analyzed using intention-to-treat.

For the main analyses, the shape of the dose-response relationship between selenium supplementation and each BTM (OC, PINP, CTX, BALP), at each time (6 months and 5 years, respectively), was investigated separately using an ANCOVA with orthogonal polynomials. Covariates included age (continuous), BMI (continuous), baseline selenium status (continuous), baseline BTM (continuous), smoking (binary), alcohol (binary), supplement use (binary; calcium, vitamin D, and multivitamins), and medication (binary; thyroid, systemic and inhaled GC, antiresorptive, and HRT). These covariates were selected based on previous literature showing their effect on bone health.⁽⁴⁰⁾ Outcomes are reported as estimated marginal means with upper and lower 95% confidence intervals after back transformation.

One participant of the 482 with BTMs was removed from the analyses. This participant's BTM concentrations for OC, PINP, CTX, and BALP were 6-, 5-, 7-, and 2-fold higher than mean concentrations. The removal of this participant had no significant effect on the main findings or baseline descriptives (data not shown). Sensitivity analyses were undertaken after excluding those participants receiving systemic GC ($n = 4$) because of their potential to influence BTMs.^(35,39,41,42) A second analysis excluded systemic GC, inhaled GC, antiresorptive, and thyroid medication users ($n = 53$). Although some research suggests inhaled GC have minimal effects on bone,⁽⁴³⁾ a recent article suggested they increased the risk of osteoporosis.⁽⁴⁴⁾ Thyroid medication has been shown to have a detrimental effect on bone health.^(45,46) Another sensitivity analysis excluded those using HRT ($n = 75$). A further sensitivity analysis removed supplement users ($n = 215$) because calcium, vitamin D, and multivitamins can influence bone metabolism. A final sensitivity analysis removed those using antiresorptives at baseline, 6 months, and 5 years, as well as those who had fractures, as a proxy to estimate those with osteoporosis ($n = 14$). The analyses were also repeated after categorizing baseline plasma selenium concentration into a binary variable, above and below 70 $\mu\text{g/L}$, based on evidence that this concentration is required to optimize glutathione peroxidase 3 (GPx) activity.⁽⁴⁷⁾ Sensitivity analyses are reported in Supplemental Tables S3–S8, respectively.

This was a secondary analysis, sample size was not determined for this particular study. The initial pilot study proposed a sample size of 500 participants.⁽³¹⁾ The selenium supplemental trial of the effects on bone turnover markers in 120 postmenopausal women conducted by Walsh and colleagues⁽³⁰⁾ was 90% powered to be able to detect 20% between-group

difference in urine N-terminal cross-linking telopeptide of type I collagen/creatinine ratio.⁽³⁰⁾ Because our study had similar outcome measures, in 481 participants, we are confident that we have sufficient power to detect any changes in BTMs after selenium supplementation. In addition, a retrospective power analysis was conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). Least significant changes were set to 20% for OC, 21% for PINP, and 30% for CTX and BALP.^(48–50) These calculations showed that we had $>90\%$ power to detect least significant changes in OC, PINP, and BALP at 6 months and 5 years, but only 5% and 16% for CTX at 6 months and 5 years, respectively.

Results

Baseline characteristics

Of the 491 participants randomized into the trial, 481 participants had BTM measurements at baseline (Fig. 1). The mean age of participants was 66.2 ± 4.1 years, and there was an almost equal split of male and female participants (52.0 versus 48.0%, $p = 0.476$, respectively) (Table 1). There were significant differences at baseline between supplementation groups for living status ($p = 0.047$), calcium supplementation ($p = 0.028$), and vitamin D supplementation ($p = 0.020$), but, otherwise, the supplementation groups were well matched (Table 1). Overall mean plasma selenium concentration at baseline was $86.5 \pm 16.2 \mu\text{g/d}$ and did not differ between groups ($p = 0.190$; Table 2). Across all supplementation groups, 12% of participants had evidence of selenium inadequacy (plasma concentration $< 70 \mu\text{g/L}$). Mean \pm (SD) baseline concentrations of OC, PINP, CTX, and BALP were 18.7 ± 8.5 , 42.7 ± 18.1 , 0.20 ± 0.22 , and $15.7 \pm 5.7 \mu\text{g/L}$, respectively (Table 3). Over the 5 years of study, 127 participants were lost to follow-up, leaving 354 for the full study duration (Fig. 1). There were no differences between supplementation groups in loss to follow-up ($p = 0.847$) or reasons for dropout ($p = 0.816$, data not shown). However, participants who dropped out were more likely to have lower selenium status at 6 months ($p = 0.009$) but not at baseline. There were no other significant differences in baseline characteristics between participants who dropped out and those who did not (Supplemental Table S9). BTM concentrations did not differ significantly between those who dropped out and those who remained in the study (Supplemental Table S10).

Effects of increasing doses of supplemental selenium on plasma selenium concentration

Over the 5 years of the study, mean \pm (SD) plasma selenium concentration in the placebo group remained unchanged (85.9 ± 15.3 , 85.2 ± 14.3 , and $87.5 \pm 24.1 \mu\text{g/L}$ at baseline, 6 months, and 5 years, respectively, $p = 0.190$; Table 2). In contrast, at 6 months, plasma selenium concentration increased significantly in a dose-dependent manner with increasing supplemental selenium to reach 152.6, 209.1, and 253.7 $\mu\text{g/L}$ for selenium doses 100–300 $\mu\text{g/d}$, respectively, and remained elevated at 5 years (Table 2).

Effects of increasing dose of supplemental selenium on concentrations of bone turnover markers

Concentrations of each of the four BTMs in serum at 6 months and at 5 years were similar to those at baseline and there was

no evidence that selenium supplementation altered any of the BTMs at either time point (Table 4). These findings remained robust in sensitivity analyses after excluding (i) users of systemic GC, (ii) combined users of systemic

GC, inhaled GC, antiresorptives, and thyroid medication, (iii) users of HRT, (iv) users of nutritional supplements, (v) users of antiresorptives at baseline, 6 months, and 5 years, and those having fractures (Supplemental Tables S3–S7).

Table 1. Baseline Characteristics of Participants with Bone Turnover Marker Measurements, Randomized to Selenium Supplementation (0–300 µg/d)

Characteristic	All participants N = 481	Selenium dosage (µg/d)				p Value
		0 n = 124	100 n = 122	200 n = 118	300 n = 117	
Male, n (%)	250 (52.0)	59 (23.6)	69 (27.6)	64 (25.6)	58 (23.3)	0.476
Female, n (%)	231 (48.0)	65 (28.1)	53 (22.9)	54 (23.4)	59 (25.5)	
Age (years), mean (SD)	66.16 (4.10)	65.42 (3.8)	66.49 (4.2)	66.32 (4.3)	66.45 (4.1)	0.155
BMI (kg/m ²) (SD)	26.83 (4.02)	26.51 (4.1)	27.01 (3.8)	27.24 (4.3)	26.51 (4.0)	0.320
Height (m), mean (SD)	1.69 (0.09)	1.68 (0.09)	1.69 (0.08)	1.70 (0.09)	1.69 (0.08)	0.538
Weight (kg), mean (SD)	76.87 (13.5)	75.41 (12.6)	76.84 (11.6)	79.21 (15.4)	75.83 (14.3)	0.255
Alcohol units per week, mean (SD)	7.30 (7.5)	7.75 (8.4)	7.75 (8.0)	7.25 (7.3)	6.37 (6.3)	0.741
Smokers, n (%)						
Never	158 (32.8)	36 (22.8)	40 (25.3)	39 (24.7)	43 (27.2)	0.590
Previous	178 (37.0)	45 (25.3)	47 (26.4)	49 (27.5)	37 (20.8)	
Present	145 (30.1)	43 (29.7)	35 (24.1)	30 (20.7)	37 (25.5)	
Education, n (%)						
No further education	134 (28.7)	38 (28.4)	41 (30.6)	30 (22.4)	25 (18.7)	0.267
1–3 years	76 (16.3)	13 (17.1)	19 (25.0)	21 (27.6)	23 (30.3)	
3–4 years	212 (45.4)	57 (26.9)	44 (20.8)	53 (25.0)	58 (27.4)	
>4 years	45 (9.6)	12 (26.7)	14 (31.1)	10 (22.2)	9 (20.0)	
Live alone, n (%)						
No	400 (85.7)	94 (23.5)	107 (26.8)	99 (24.8)	100 (25.2)	0.047
Yes	67 (14.3)	26 (38.8)	11 (16.4)	15 (22.4)	15 (22.4)	
Thyroid medication, n (%)						
None	467 (97.1)	122 (26.1)	118 (25.3)	113 (24.2)	114 (24.4)	0.659
LT4	11 (2.3)	2 (18.2)	3 (27.3)	3 (27.3)	3 (27.3)	
ATD	3 (0.6)	0 (0.0)	1 (33.3)	2 (66.7)	0 (0.0)	
Inhaled GC, n (%)						
No	450 (96.4)	118 (26.2)	111 (24.7)	110 (24.4)	111 (24.7)	0.374
Yes	17 (3.6)	2 (11.8)	7 (41.2)	4 (23.5)	4 (23.5)	
Systemic GC, n (%)						
No	475 (99.2)	122 (25.7)	121 (25.5)	117 (24.6)	115 (24.2)	0.595
Yes	4 (0.8)	2 (50.0)	1 (25.0)	0 (0.0)	1 (25.0)	
Antiresorptives, n (%)						
No	461 (98.7)	118 (25.6)	117 (25.4)	113 (24.5)	113 (24.7)	0.884
Yes	6 (1.3)	2 (33.3)	1 (16.7)	1 (16.7)	2 (33.3)	
HRT, n (%)						
No	392 (83.9)	98 (25.0)	98 (25.0)	99 (25.3)	97 (24.7)	0.740
Yes	75 (16.1)	22 (29.3)	20 (26.7)	15 (20.0)	18 (24.0)	
Calcium, n (%)						
No	419 (89.7)	110 (26.3)	112 (26.7)	95 (22.7)	102 (24.3)	0.028
Yes	48 (10.3)	10 (20.8)	6 (12.5)	19 (39.6)	13 (27.1)	
Vitamin D, n (%)						
No	442 (94.6)	115 (26.0)	117 (26.5)	103 (23.3)	107 (24.2)	0.020
Yes	25 (5.4)	5 (20.0)	1 (4.0)	11 (44.0)	8 (32.0)	
Multivitamin, n (%)						
No	325 (69.6)	90 (27.7)	86 (26.5)	70 (21.5)	79 (24.3)	0.116
Yes	142 (30.4)	30 (21.1)	32 (22.5)	44 (31.0)	36 (25.4)	
Dropout, n (%)						
6 months	23 (18.1)	10 (43.5)	2 (8.7)	5 (21.7)	6 (26.1)	0.133
5 years	104 (81.9)	26 (25.0)	30 (28.8)	26 (25.0)	22 (21.2)	

ATD = antithyroid drugs; BMI = body mass index; HRT = hormone replacement therapy; inhaled GC = inhaled glucocorticoid; LT4 = levothyroxine; SD = standard deviation; systemic GC = systemic glucocorticoid.

Age, alcohol n = 481; height, weight, BMI n = 478; smoking, sex, thyroid medication n = 480; BMI, weight, height n = 478; systemic GC n = 479; education, live alone, inhaled GC, antiresorptives, HRT and supplement users n = 467.

Table 2. Plasma Selenium Concentration at Baseline, 6-Month, and 5-Year Measurements for Participants With Bone Turnover Marker Measurements Randomized to Selenium Supplementation (0–300 µg/d)

Selenium status (µg/L), mean (SD)	All participants	Selenium dosage (µg/d)				<i>p</i> Value
		0	100	200	300	
Baseline (<i>n</i> = 479)	86.5 (16.2)	85.9 (15.3)	87.8 (16.2)	88.3 (16.4)	84.0 (16.9)	0.190
6 months (<i>n</i> = 426)	174.1 (72.4)	85.2 (14.3)	152.6 (23.7)	209.1 (42.2)	253.7 (53.7)	<0.001
5 years (<i>n</i> = 349)	185.6 (85.4)	87.5 (24.1)	158.4 (28.4)	222.4 (41.1)	275.9 (78.9)	<0.001

Baseline selenium status *n* = 479: 124, 122, 117, 116; 6 months *n* = 426: 106, 112, 106, 102; 5 years *n* = 349: 88, 88, 86, 87 for 0–300 µg/d selenium, respectively.

Table 3. Plasma Concentration of Bone Turnover Markers at Baseline for Participants Randomized to Selenium Supplementation (0–300 µg/d)

Bone turnover (µg/L), mean (SD)	All participants (<i>N</i> = 481)	Selenium dosage (µg/d)				<i>p</i> Value
		0	100	200	300	
OC	18.7 (8.5)	19.1 (8.2)	18.3 (8.3)	18.0 (8.8)	19.3 (8.5)	0.321
PINP	42.7 (18.1)	43.4 (19.3)	43.0 (16.4)	41.6 (19.8)	42.7 (16.5)	0.629
CTX	0.20 (0.22)	0.21 (0.13)	0.18 (0.11)	0.22 (0.40)	0.21 (0.14)	0.167
BALP	15.7 (5.7)	15.3 (5.5)	15.8 (5.7)	15.6 (5.4)	16.0 (6.2)	0.901

BALP = bone alkaline phosphatase; CTX = collagen type 1 cross-linked C-telopeptide; OC = osteocalcin; PINP = procollagen type 1 N-terminal propeptide; SD = standard deviation.

OC and PINP *n* = 481: 124, 122, 118, 117; CTX *n* = 459: 118, 117, 110, 114; BALP *n* = 479: 124, 121, 117, 117 for 0–300 µg/d selenium, respectively.

When analyses were limited to participants with plasma selenium status below 70 µg/L, supplementation had a marginal, significant effect on CTX concentrations at 5 years (Supplemental Table S8).

Adverse events

Adverse events for the full study have been reported and consisted of grooved nails, hair loss, and skin reactions.^(31,32) During the 5 years, 22 (4.6%) participants with BTM measurements died and 57 (11.9%) withdrew due to nonfatal adverse events and reactions (Fig. 1) with no significant differences between supplementation groups (*p* = 0.727).

Discussion

In this RCT of selenium supplementation in older Danish adults, plasma selenium concentration did not have a significant effect on BTMs.

These results are consistent with findings from a RCT of selenium supplementation for 6 months in older women in the UK.⁽³⁰⁾ That study recruited 120 osteoporotic and osteopenic postmenopausal women (aged 55 to 83 years) with a baseline plasma selenium concentration (79.4 µg/L) similar to our present study (86.5 µg/L) and found no effect of selenium supplementation on any of the measured BTMs.⁽³⁰⁾

The plasma selenium concentration for optimal bone health is not known with certainty. However, if it is assumed that the

Table 4. Estimated Marginal Means From ANCOVA of Bone Turnover Markers by Supplementation Group at 6 Months and 5 Years

Bone turnover (µg/L), mean (CI)	Selenium dosage (µg)				<i>p</i> Value
	0	100	200	300	
OC 6 months	17.1 (16.3–17.9)	16.7 (16.0–17.5)	17.5 (16.6–18.3)	16.5 (15.7–17.3)	0.373
OC 5 years	16.9 (15.6–18.2)	17.1 (15.8–18.6)	17.1 (15.7–18.6)	16.0 (14.8–17.3)	0.630
PINP 6 months	38.7 (36.8–40.8)	36.6 (34.7–38.5)	38.4 (36.4–40.5)	38.6 (36.6–40.8)	0.370
PINP 5 years	39.5 (36.1–43.3)	40.0 (36.5–43.8)	39.4 (35.8–43.3)	37.6 (34.3–41.1)	0.793
CTX 6 months	0.16 (0.14–0.17)	0.16 (0.14–0.17)	0.16 (0.15–0.18)	0.15 (0.14–0.17)	0.910
CTX 5 years	0.16 (0.14–0.18)	0.17 (0.15–0.19)	0.16 (0.14–0.18)	0.15 (0.14–0.19)	0.582
BALP 6 months	14.4 (13.8–14.9)	13.7 (13.2–14.3)	13.7 (13.2–14.3)	14.3 (13.7–14.9)	0.170
BALP 5 years	14.0 (13.2–14.8)	14.8 (14.0–15.7)	14.5 (13.6–15.4)	14.5 (13.7–15.3)	0.525

CI = confidence intervals; OC = osteocalcin; PINP = procollagen type 1 N-terminal propeptide; CTX = collagen type 1 cross-linked C-telopeptide; BALP = bone alkaline phosphatase.

Upper and lower 95% confidence intervals are displayed in parentheses.

Covariates in the ANCOVA included age (continuous), body mass index (continuous), baseline selenium status (continuous), baseline bone turnover marker (continuous), smoking (binary), alcohol (binary), supplement use (binary) (calcium, vitamin D, and multivitamins) and medication (binary) (thyroid, inhaled and systemic glucocorticoid [GC], antiresorptives, hormone replacement therapy [HRT]). OC 6 months *n* = 404: 107, 105, 98, 94; OC 5 years *n* = 328: 84, 84, 76, 84; PINP 6 months *n* = 403: 106, 105, 98, 94; PINP 5 years *n* = 328: 84, 84, 76, 84; CTX 6 months *n* = 378: 99, 98, 93, 88; CTX 5 years *n* = 299: 74, 77, 73, 75; BALP 6 months *n* = 402: 106, 104, 98, 94; BALP 5 years *n* = 328: 84, 83, 77, 84 participants for 0–300 µg/d selenium, respectively.

concentration that is adequate for wider aspects of health ($\geq 70 \mu\text{g/L}$ ⁽⁴⁷⁾) is also adequate for bone, then it is likely that only a small minority of PRECISE study participants (12.1%) had potential to benefit from selenium supplementation. Studies that have observed responses to selenium, such as cancer prevalence or BMD, are usually in populations with suboptimal intakes or status, whereas replete populations are less responsive or nonresponsive.⁽⁵¹⁻⁵³⁾ The relatively high baseline selenium concentration ($\geq 70 \mu\text{g/L}$ ⁽⁴⁷⁾) in the present study may explain the lack of response in BTMs to selenium supplementation.

Specific forms of selenium that have been used for supplementation studies differ in their bioavailability.⁽⁵⁴⁾ For example, sodium selenite was used by Walsh and colleagues,⁽³⁰⁾ whereas selenium yeast was used in our study and the Nutritional Prevention of Cancer Study.⁽⁵⁵⁾ Our supplement contained 54% to 60% SeMet⁽³⁴⁾; studies suggest that the bioavailability of SeMet is more than 90%, whereas it is around 50% for the inorganic forms, selenite and selenate.⁽⁵⁶⁾ Selenium yeast is one of the most bioavailable forms of selenium with high efficiency in increasing selenoenzyme activity.^(57,58) Therefore, it is unlikely that the lack of effect of selenium supplementation on BTMs observed in the present study was attributable to low selenium bioavailability. Indeed, supplementation raised plasma selenium concentration in a dose-dependent manner ($p > 0.001$).

Among the strengths of our study, to our knowledge, this is the first, long-term (5 years), large-scale RCT exploring the effects of selenium supplementation on BTMs in older men and women. There was a large dose-dependent increase in plasma selenium concentration with supplementation, suggesting compliance was good. This was gauged by the linear increase in selenium concentration with an increasing daily dose at 6 months, which was maintained at 5 years. In contrast, the plasma selenium concentration remained similar to baseline in the placebo group. Plasma selenium concentration is a robust indicator of selenium status⁽⁵⁹⁾ and correlates well with recent intakes of organic selenium.⁽⁶⁰⁾ The use of BTMs can help determine metabolic imbalances within bone, fracture risk, and detect nonresponders to treatment. Using a range of biomarkers allowed us to overcome some of the individual limitations of each BTM to provide a more representative finding, as well as using markers suggested by the IOF.^(35,36)

A limitation of our study was the use of nonfasted blood samples as feeding can decrease BTMs.⁽⁶¹⁾ Circadian rhythm can also affect BTMs, especially markers of bone resorption, for which concentrations are highest in the morning.⁽⁶²⁻⁶⁵⁾ Consequently, the use of nonfasted samples may increase the variance in BTM measurements, but this is likely to be similar for all supplementation groups. We have no information on dietary intakes of other nutrients that influence bone health, such as calcium and vitamin D,^(40,66) although we were able to adjust for supplementation with calcium, vitamin D, and multivitamins. We do not have data on BMI change through the study, but mean values at baseline were similar for all supplement groups, so this is unlikely to have been a confounder. Our participants were aged 60 to 74 years at baseline and so we are unable to generalize our results to older populations among whom osteoporosis and micronutrient deficiencies are more likely.^(40,67) Future studies exploring the effects of selenium supplementation on bone health should consider including older people with lower baseline selenium status and/or those with inflammatory conditions who are at greater risk of osteoporosis and who may be more responsive to selenium supplementation.

This was the first long-term (5 years) RCT exploring the effects of selenium supplementation on BTMs in healthy older adults. Selenium supplementation did not have any significant effect on BTMs. We cannot rule out the potential of selenium supplementation to improve bone health in adults with lower selenium status and/or poorer bone health at baseline.

Disclosures

RE received consultancy funding from IDS, Sandoz, Samsung, Haoma Medica, CL Bio, Biocon, Coherus, and Takeda; meeting presentations for Pharmacosmos, Alexion, and Amgen; and grant funding from Roche, Pharmacosmos, and Alexion. JSW received speaker's honoraria from Eli Lilly and Sandoz, grant funding from Alexion, donation of drug from Eli Lilly for clinical studies, and consulting fees from Mereo Biopharma. All other authors state that they have no conflicts of interest.

Acknowledgments

We acknowledge Professor Kim Overvad for planning of the DK PRECISE pilot trial, Ann Knoop for inputting the earlier phases, and Peter Schnohr for collecting data from the Copenhagen City Heart Study.

Support for the study came from the Danish Cancer Society; the Research Foundation of the County of Funen; Cypress Systems Inc.; the Danish Veterinary and Food Administration; the Council of Consultant Physicians, Odense University Hospital; the Clinical Experimental Research Foundation at Department of Oncology, Odense University Hospital; K.A Rohde's Foundation; and Dagmar Marshall's Foundation. The selenium and placebo tablets were provided by Pharma Nord ApS, Vejle, Denmark. Immunodiagnostic Systems (Baldon, UK) provided the reagents for the BTMs. We thank The MRC-Versus Arthritis Centre for Integrated Research into Musculoskeletal Aging (CIMA) (<https://www.cimauk.org/>) for funding the PhD program of study associated with this research. We also acknowledge the generous donations provided by Cumbria Community Foundation and Beverley Charitable Trust Fund throughout the associated PhD program of study. No funder had any role in the design, analysis, or writing of this article.

Authors' roles: RE, JSW, FG, LF, JF, and KW designed the research. RE, FG, FC, KW, and SC conducted the research. GP performed statistical analysis. GP, TRH, and JCM wrote the manuscript. GP had primary responsibility for final content. GP, TRH, JCM, FC, KHW, LF, SC, RE, and JSW revised the manuscript. All authors read and approved the final manuscript.

Author Contributions

Giorgia Perri: Formal analysis; writing – original draft; writing – review and editing. **Tom R Hill:** Supervision; writing – review and editing. **John C Mathers:** Supervision; writing – review and editing. **Jennifer S Walsh:** Conceptualization; data curation; funding acquisition; writing – review and editing. **Fatma Gossiel:** Conceptualization; data curation; investigation; writing – review and editing. **Kristian Winther:** Conceptualization; data curation; investigation; supervision; writing – review and editing. **Jacob Frølich:** Conceptualization; data curation; writing – review and editing. **Lars Folkestad:** Conceptualization; data curation; writing – review and editing. **Søren Cold:** Investigation;

writing – review and editing. **Richard Eastell**: Conceptualization; data curation; funding acquisition; writing – review and editing.

Peer Review

The peer review history for this article is available at <https://publons.com/publon/10.1002/jbmr.4703>.

Data Availability Statement

The data that support the findings of this study are not openly available.

References

1. Combs GF Jr. Selenium in global food systems. *Br J Nutr*. 2001;85(5):517-547.
2. Rayman MP. The argument for increasing selenium intake. *Proc Nutr Soc*. 2002;61(2):203-215.
3. Joint Food Safety and Standards Group. Dietary intake of selenium food surveillance information sheet no. 126. London: Ministry of Agriculture, Fisheries and Food; 1997.
4. Bro S, Sandström B, Heydorn K. Intake of essential and toxic trace elements in a random sample of Danish men as determined by the duplicate portion sampling technique. *J Trace Elem Electrolytes Health Dis*. 1990;4(3):147-155.
5. Andersen N, Fagt S, Groth M, et al. [Food habits in Denmark 1995: main results] [Danish]. Publikation LST Levnedsmiddelstyrelsen (Denmark) no. 235. 1996.
6. Lyhne N, Christensen T, Groth M, et al. Danskernes kostvaner 2000–2002. Hovedresultater (DFV Publikation nr 11 Danish Institute for Food and Veterinary Research [Dietary habits in Denmark 2000–2002: main results] [Danish]). 2005.
7. Danish National Survey of Dietary Habits and Physical Activity 2003, 2015. [Internet]. Available at: <https://www.food.dtu.dk/english/publications/nutrition/danish-national-survey-of-dietary-habits-and-physical-activity>. Accessed 15 June 2022.
8. Brown MR, Cohen HJ, Lyons JM, et al. Proximal muscle weakness and selenium deficiency associated with long term parenteral nutrition. *Am J Clin Nutr*. 1986;43(4):549-554.
9. Lauretani F, Semba RD, Bandinelli S, Ray AL, Guralnik JM, Ferrucci L. Association of low plasma selenium concentrations with poor muscle strength in older community-dwelling adults: the InCHIANTI study. *Am J Clin Nutr*. 2007;86(2):347-352.
10. Yang C, Wolf E, Roser K, Delling G, Muller PK. Selenium deficiency and fulvic acid supplementation induces fibrosis of cartilage and disturbs subchondral ossification in knee joints of mice: an animal model study of Kashin-Beck disease. *Virchows Arch A Pathol Anat Histopathol*. 1993;423(6):483-491.
11. Hurt HD, Cary EE, Visek WJ. Growth, reproduction, and tissue concentrations of selenium in the selenium-depleted rat. *J Nutr*. 1971;101(6):761-766.
12. Ewan RC. Effect of selenium on rat growth, growth hormone and diet utilization. *J Nutr*. 1976;106(5):702-709.
13. Thompson KM, Haibach H, Sunde RA. Growth and plasma triiodothyronine concentrations are modified by selenium deficiency and repletion in second-generation selenium-deficient rats. *J Nutr*. 1995;125(4):864-873.
14. Cao JJ, Gregoire BR, Zeng H. Selenium deficiency decreases antioxidative capacity and is detrimental to bone microarchitecture in mice. *J Nutr*. 2012;142(8):1526-1531.
15. Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. *Biochim Biophys Acta*. 2009;1790(11):1478-1485.
16. Hariharan S, Dharmaraj S. Selenium and selenoproteins: its role in regulation of inflammation. *Inflammopharmacology*. 2020;28(3):667-695.
17. Tseng CK, Ho CT, Hsu HS, et al. Selenium is inversely associated with interleukin-6 in the elderly. *J Nutr Health Aging*. 2013;17(3):280-284.
18. Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. *Front Endocrinol*. 2018;9:788.
19. Kitauro H, Marahleh A, Ohori F, et al. Osteocyte-related cytokines regulate osteoclast formation and bone resorption. *Int J Mol Sci*. 2020;21(14):5169.
20. Zhang Z, Zhang J, Xiao J. Selenoproteins and selenium status in bone physiology and pathology. *Biochim Biophys Acta*. 2014;1840(11):3246-3256.
21. Beukhof CM, Medici M, van den Beld AW, et al. Selenium status is positively associated with bone mineral density in healthy aging European men. *PLoS One*. 2016;11(4):e0152748.
22. Cervellati C, Bonaccorsi G, Cremonini E, et al. Oxidative stress and bone resorption interplay as a possible trigger for postmenopausal osteoporosis. *Biomed Res Int*. 2014;2014:569563.
23. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. *Endocr Rev*. 2010;31(3):266-300.
24. Prystupa A, Kicinski P, Luchowska-Kocot D, et al. Association between serum selenium concentrations and levels of proinflammatory and profibrotic cytokines-interleukin-6 and growth differentiation factor-15, in patients with alcoholic liver cirrhosis. *Int J Environ Res Public Health*. 2017;14(4):437.
25. Salehi M, Sohrabi Z, Ekramzadeh M, et al. Selenium supplementation improves the nutritional status of hemodialysis patients: a randomized, double-blind, placebo-controlled trial. *Nephrol Dial Transplant*. 2013;28(3):716-723.
26. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. *J Clin Endocrinol Metab*. 2001;86(5):2032-2042.
27. Ferrari SL, Ahn-Luong L, Garnerio P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. *J Clin Endocrinol Metab*. 2003;88(1):255-259.
28. Hoeg A, Gogakos A, Murphy E, et al. Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. *J Clin Endocrinol Metab*. 2012;97(11):4061-4070.
29. Wu CC, Wang CK, Yang A-M, Lu CS, Lin CY. Selenium status is independently related to bone mineral density, FRAX score, and bone fracture history: NHANES, 2013 to 2014. *Bone*. 2021;143:115631.
30. Walsh JS, Jacques RM, Schomburg L, et al. Effect of selenium supplementation on musculoskeletal health in older women: a randomised, double-blind, placebo-controlled trial. *Lancet Healthy Longev*. 2021;2(4):e212-e221.
31. Cold F, Winther KH, Pastor-Barriuso R, et al. Randomised controlled trial of the effect of long-term selenium supplementation on plasma cholesterol in an elderly Danish population. *Br J Nutr*. 2015;114(11):1807-1818.
32. Rayman MP, Winther KH, Pastor-Barriuso R, et al. Effect of long-term selenium supplementation on mortality: results from a multiple-dose, randomised controlled trial. *Free Radicals Biol Med*. 2018;1(127):46-54.
33. Institute of Medicine Panel on Dietary Antioxidants and Related Compounds. Dietary reference intakes for vitamin c, vitamin e, selenium, and carotenoids. Washington, DC: National Academies Press; 2000.
34. Larsen EH, Hansen M, Paulin H, Moesgaard S, Reid M, Rayman M. Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies. *J AOAC Int*. 2004;87(1):225-232.
35. Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. *Health Technol Assess*. 2014;18(11):1-180.

36. Vasikaran S, Cooper C, Eastell R, et al. *Int Osteoporos*. 2011;49(8):1271-1274.
37. Nizet A, Cavalier E, Stenvinkel P, Haarhaus M, Magnusson P. Bone alkaline phosphatase: an important biomarker in chronic kidney disease-mineral and bone disorder. *Clin Chim Acta*. 2020;501:198-206.
38. Park SY, Ahn SH, Yoo JI, et al. Clinical application of bone turnover markers in osteoporosis in Korea. *J Bone Metab*. 2019;26(1):19-24.
39. Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA. Diagnosis of endocrine disease: bone turnover markers: are they clinically useful? *Eur J Endocrinol*. 2018;178(1):R19-R31.
40. Aspray TJ, Hill TR. Osteoporosis and the ageing skeleton. *Subcell Biochem*. 2019;91:453-476.
41. Barahona MJ, Sucunza N, Resmini E, et al. Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. *J Bone Miner Res*. 2009;24(11):1841-1846.
42. Devogelaer JP, Durnez A, Gruson D, Manicourt DH, Bone turnover markers and glucocorticoid treatments. In: Patel V, Preedy V, editors. *Biomarkers in bone disease. biomarkers in disease: methods, discoveries and applications*. Dordrecht: Springer; 2017 pp 905-932.
43. Loke YK, Gilbert D, Thavarajah M, Blanco P, Wilson AM. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. *BMJ Open*. 2015;5(11):e008554.
44. Chiu KL, Lee CC, Chen CY. Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan. *Sci Rep*. 2021;11(1):724.
45. Karimifar M, Esmaili F, Salari A, Kachuei A, Faragzadegan Z, Karimifar M. Effects of levothyroxine and thyroid stimulating hormone on bone loss in patients with primary hypothyroidism. *J Res Pharm Pract*. 2014;3(3):83-87.
46. Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. *BMJ*. 2011;342:d2238.
47. Nève J. Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. *J Trace Elem Med Biol*. 1995;9(2):65-73.
48. Schousboe JT, Bauer DC. Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy. *Curr Osteoporos Rep*. 2012;10:56-63.
49. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH. PINP as an aid for monitoring patients treated with teriparatide. *Bone*. 2011;48(4):798-803.
50. Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. *Int J Clin Pract*. 2009;63(1):19-26.
51. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial. *BJU Int*. 2003;91(7):608-612.
52. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). *JAMA*. 2009;301(1):39-51.
53. Galvez-Fernandez M, Grau-Perez M, Garcia-Barrera T, et al. Arsenic, cadmium, and selenium exposures and bone mineral density-related endpoints: the HORTEGA study. *Free Radicals Biol Med*. 2021;162:392-400.
54. Fairweather-Tait SJ, Collings R, Hurst R. Selenium bioavailability: current knowledge and future research requirements. *Am J Clin Nutr*. 2010;91(5):1484S-1491S.
55. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA*. 1996;276(24):1957-1963.
56. Thomson CD. Urinary and fecal excretions and absorption of a large supplement of selenium: superiority of selenate over selenite. *Am J Clin Nutr*. 1986;44(5):659-663.
57. Clausen J, Nielsen SA. Comparison of whole blood selenium values and erythrocyte glutathione peroxidase activities of normal individuals on supplementation with selenate, selenite, L-selenomethionine, and high selenium yeast. *Biol Trace Elem Res*. 1988;15:125-138.
58. Thomson CD, Robinson MF, Butler JA, Whanger PD. Long-term supplementation with selenate and selenomethionine: selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New Zealand women. *Br J Nutr*. 1993;69(2):577-588.
59. Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. *Cancer Epidemiol Biomarkers Prev*. 2006;15(4):804-810.
60. Hurst R, Collings R, Harvey LJ, et al. EURRECA-estimating selenium requirements for deriving dietary reference values. *Crit Rev Food Sci Nutr*. 2013;53(10):1077-1096.
61. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. *Bone*. 2002;30(6):886-890.
62. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. *Eur J Endocrinol*. 1999;140(4):332-337.
63. Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. *Clin Chem*. 2000;46(3):431.
64. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. *Osteoporos Int*. 2000;11(Suppl 6):S30-S44.
65. Scott JP, Sale C, Greeves JP, Casey A, Dutton J, Fraser WD. Effect of fasting versus feeding on the bone metabolic response to running. *Bone*. 2012;51(6):990-999.
66. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. *J Bone Miner Res*. 1996;11(3):337-349.
67. De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA. Bone density and risk of hip fracture in men and women: cross sectional analysis. *BMJ*. 1997;315(7102):221-225.